TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers report that DT-109 reduced signs of metabolic dysfunction-associated steatohepatitis (MASH) in mice and nonhuman primates by changing gut bacteria and strengthening the intestinal barrier. The results are from animal studies; whether the drug is safe and effective in people is not established.
An experimental compound called DT-109 reduced MASH in mice and nonhuman primates by altering gut bacteria and reinforcing the intestinal lining, according to a study from Michigan Medicine published in The Journal of Clinical Investigation. The findings point to a possible way to affect liver disease through the gut, but they do not show that the drug works or is safe in people.
The researchers found that DT-109 lowered levels of Clostridium perfringens, a gut bacterium that produces ammonia, and reduced ammonia in the intestines of the animals. The study describes a chain of effects in which excess ammonia can weaken the gut’s protective barrier, allowing microbial products to enter the bloodstream and reach the liver. There, those substances may contribute to inflammation and liver injury.
With the barrier strengthened, fewer potentially harmful microbial substances moved from the digestive tract into the body, the researchers reported. In nonhuman primates, DT-109 was associated with less liver inflammation and milder MASH. The team also reported protective effects in mice. These findings build on earlier animal research by the group suggesting that DT-109 could improve MASH, while the new study investigates how the compound may produce those effects.
DT-109 is a glycine-based tripeptide, a small molecule made of three amino acids. The research team says it acts primarily in the gastrointestinal tract, with effects on the liver arising through the biological connection between the gut and liver. The study did not establish a human dose, clinical benefit, or safety profile.
A Gut-Based Route to Liver Protection
MASH is a serious form of fatty liver disease involving excess liver fat, inflammation, and cell damage. It can progress to cirrhosis, liver cancer, or liver failure. The source report estimates that MASH affects about 7% of the world’s population, while noting that effective treatment options remain limited.
The animal findings matter because they suggest that liver injury may be reduced by addressing processes outside the liver itself. If future research confirms the mechanism in people, targeting gut microbes or the intestinal barrier could add a different approach to managing MASH. For now, this is a research possibility—not a treatment option for patients—and the animal results cannot predict whether people will benefit.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Hyperice Normatec 3 Leg Compression Boots – Full Leg Recovery, Standard Size
As an affiliate, we earn on qualifying purchases.
How the Gut May Affect MASH
The liver receives substances absorbed from the intestines through the bloodstream, creating what researchers call the gut-liver axis. In the mechanism described by this study, ammonia and other microbial products can pass through a weakened intestinal barrier and contribute to liver inflammation. The researchers also describe excessive activation of CD8+ T cells, immune cells that can contribute to inflammatory damage when overactive.
The team’s earlier animal work had indicated that DT-109 could improve MASH, but the reasons for that effect were not clear. The new study links the compound’s activity to changes in gut bacteria, lower ammonia production, and improved barrier integrity. The authors also point to previous nonhuman-primate studies involving atherosclerotic plaques and vascular calcification. Those results are separate findings and do not establish that DT-109 treats cardiovascular disease in people.
“We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression.”
— Eugene Chen, senior author and professor of cardiovascular medicine at the University of Michigan Medical School
Human Evidence Is Still Missing
The reported results come from mice and nonhuman primates, not clinical trials in people. The source material provides no evidence about human safety, side effects, effective dosing, or whether any improvement would last. It also does not report whether the research team has begun or plans a specific human trial.
The study’s findings support a proposed mechanism, but they do not establish that the same bacterial changes or barrier effects will produce comparable outcomes in patients. The report also does not specify how the animal results translate into the range of MASH severity or other health conditions seen in people.
Clinical Testing Would Be Needed
The next step toward any potential use in patients would be further development and human clinical testing, including studies of safety and dose before researchers could determine whether DT-109 improves MASH in people. No human trial timeline or treatment approval is given in the source report.
Until such evidence is available, DT-109 should be understood as an experimental compound studied in animals, not an established therapy. Researchers will also need to clarify whether the proposed gut-based mechanism holds in humans and whether the compound’s effects extend beyond the outcomes measured in these animal studies.
Key Questions
What is DT-109?
DT-109 is an experimental glycine-based tripeptide studied for its effects on MASH. In the reported animal experiments, it changed gut bacteria and helped protect the intestinal barrier.
Did the drug reverse fatty liver disease in people?
No human results are reported. The study found improvements in animal models, including mice and nonhuman primates; human safety and effectiveness remain unknown.
How could repairing the gut affect the liver?
The researchers say a weakened intestinal barrier can let ammonia and other microbial products enter the bloodstream and reach the liver. DT-109 reduced these gut-related factors in the animals, alongside reduced liver inflammation.
What is MASH?
MASH, or metabolic dysfunction-associated steatohepatitis, is a severe form of fatty liver disease involving fat buildup, inflammation, and liver cell damage. It can progress to cirrhosis, liver cancer, or liver failure.
Source: rss
